1. The first successful case of ABO-incompatible living-donor lobar lung transplantation following desensitization therapy.
- Author
-
Nakajima D, Yuasa I, Kayawake H, Tanaka S, Yamada Y, Yutaka Y, Hamaji M, Ohsumi A, Ikeda T, Suga T, Baba S, Hiramatsu H, and Date H
- Subjects
- Humans, Female, Adolescent, Treatment Outcome, Rituximab, Immunosuppressive Agents, Living Donors, Lung Transplantation adverse effects
- Abstract
ABO-incompatible (ABO-I) living-donor lobar lung transplantation (LDLLT) was successfully performed in a 14-year-old girl who suffered from bronchiolitis obliterans due to graft-versus-host disease following hematopoietic stem cell transplantation. In the ABO-I LDLLT procedure, the blood type O patient received a right lower lobe donated from her blood type B father and a left lower lobe donated from her blood type O mother. Desensitization therapy, using rituximab, immunosuppressants, and plasmapheresis, was implemented for 3 weeks prior to transplantation to reduce the production of anti-B antibodies in the recipient and prevent acute antibody-mediated rejection after ABO-I LDLLT., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Shabih Manzar reports was provided by LSU Health Shreveport., (Copyright © 2023 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF